Beam Therapeutics Inc. balance sheet BEAM

Annual Quarterly

As of Sep 30, 2026, Beam Therapeutics Inc. had total assets of $1.3 billion and total liabilities of $316.4 million. Total assets were down 3.2% from a year earlier. Stockholders' equity was $952.7 million. It held $1.0 billion in cash and investments against $243.9 million of total debt, net cash of $800.0 million. The current ratio, current assets divided by current liabilities, was 13.00.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Assets
Cash
213
-20.4%
220
-22.1%
288
-45.4%
295
+4.6%
268
+16.4%
282
-3.6%
528
+83.4%
282
-35.3%
Short-term investments
831
+2.9%
933
+7.5%
923
+33.4%
950
807
+16.0%
868
+21.4%
692
-14.2%
—
Cash and investments
1,044
-2.9%
1,153
+0.2%
1,212
-0.7%
1,245
+341.6%
1,075
+16.1%
1,150
+14.1%
1,220
+11.5%
282
-35.3%
Total current assets
1,067
-2.8%
1,179
+0.3%
1,267
+1.6%
1,269
+44.5%
1,099
+16.2%
1,175
+14.2%
1,248
+11.2%
878
-27.5%
Property and equipment, net
94
-13.2%
98
-10.3%
101
-7.6%
104
-6.2%
108
-4.6%
109
-7.4%
110
-9.4%
111
-10.8%
Total assets
1,269
-3.2%
1,386
-0.3%
1,481
+0.9%
1,481
+34.2%
1,311
+11.9%
1,391
+10.3%
1,467
+7.9%
1,104
-24.4%
Liabilities and equity
Accounts payable
20
+111.1%
13
+24.1%
12
+59.6%
10
+164.3%
10
+150.4%
11
+138.3%
8
+175.9%
4
+139.4%
Total current liabilities
82
-55.0%
81
-53.6%
75
-47.3%
97
-46.8%
183
+9.8%
174
-1.8%
142
-24.4%
182
-11.4%
Total liabilities
316
-8.3%
319
-7.4%
316
-8.0%
243
-34.4%
345
-9.2%
344
-15.4%
344
-23.0%
370
-22.6%
Stockholders' equity
953
-2.1%
1,067
+1.3%
1,164
+3.1%
1,238
+68.8%
973
+22.9%
1,053
+23.3%
1,129
+23.6%
734
-25.2%
Debt
Long-term debt
100
100
100
—
—
—
—
—
Lease liabilities
144
-5.2%
147
-5.0%
151
-4.7%
154
-4.5%
151
-6.6%
155
-6.3%
158
-5.9%
161
-6.5%
Total debt
244
+61.1%
247
+59.8%
251
+58.6%
154
-4.5%
151
-6.6%
155
-6.3%
158
-5.9%
161
-6.5%
Net cash
800
-13.4%
906
-9.0%
961
-9.5%
1,091
+805.2%
924
+20.9%
996
+18.1%
1,062
+14.6%
121
-54.2%
Ratios
Current ratio
13.00x
14.57x
16.99x
13.09x
6.02x
6.75x
8.81x
4.82x
Debt to equity
0.26x
0.23x
0.22x
0.12x
0.16x
0.15x
0.14x
0.22x
Return on equity
-11.37%
-8.11%
-5.67%
-6.46%
-42.50%
-37.74%
-34.21%
-51.36%
Return on assets
-8.54%
-6.24%
-4.46%
-5.40%
-31.53%
-28.57%
-26.34%
-34.13%
Book value per share
9.21
10.34
11.33
12.17
9.60
10.45
11.23
8.77
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
BEAM (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Cambridge, MA
SEC filer status
Large accelerated filer
SEC CIK
1745999
Former names
Beam Therapeutics Inc. (until Nov 3, 2026)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.